Capital Flow Monitor · Sponsors · CIK 1943061
SYNTIS BIO, INC.
135 MORRISSEY BLVD, BOSTON, MA, 02125 · 857-675-1109
Biotechnology · Corporation· inc. DELAWARE true 2022
Fit score
—
Offering
$26.5M
Sold
$25.0M
% sold
94.3%
Investors
12
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-07-02 | D ·current | 506(b) | $26.5M | $25.0M | 94.3% | 12 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Rahul Dhanda — Executive Officer / Director, Boston, MA
-
Robert Langer — Director, Boston, MA
3 other raises
- Noveome Biotherapeutics, Inc. $6.8M of $15.0M · 45.0%
- EpiBone, Inc. $4.3M of $4.3M · 99.7%
- VitaKey Inc. $0 of $43.5M · 0.0%
-
Carlo Giovanni Traverso — Director, Boston, MA
1 other raise
- Absco Therapeutics, Inc. $5.0M of $5.0M · 100.0%
-
Teymour Boutros-Ghali — Director, Boston, MA
2 other raises
- BOLD Hark, LLC $3.1M of $3.1M · 100.0%
- Gallant Pet, Inc. $10.2M of $18.0M · 56.5%
- Martin Madaus — Director, Boston, MA
-
Teymour Boutros-Ghali — Director, Boston, MA
2 other raises
- BOLD Hark, LLC $3.1M of $3.1M · 100.0%
- Gallant Pet, Inc. $10.2M of $18.0M · 56.5%
-
Chenny Zhang — Director, Boston, MA
2 other raises
- Virchow Medical, Inc. $4.1M of $4.1M · 100.0%
- Ansa Biotechnologies, Inc. $46.4M of $56.9M · 81.6%
- Michael Nannizzi — Director, Boston, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.